Back to search results
NCT05041309

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by Invitation
Not specifiedAll AgesObservational
Kite, A Gilead Company
~1,000 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:Axicabtagene CiloleucelBrexucabtagene AutoleucelAnitocabtagene autleucelKITE-753KITE-197KITE-363

At a glance

Recruiting sites
0 of 90 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)
Measured over Up to 15 years
+4 more outcomes measured

Conditions

Solid and Hematological Malignancies

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT05041309

Where you'd take part

This study runs at 90 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Amsterdam Universitair Medische Centra (UMC)

    Amsterdam, Netherlandsno site contact published

  • Ann& Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinoisno site contact published

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italyno site contact published

  • Banner MD Anderson Cancer Center

    Gilbert, Arizonano site contact published

  • Baylor University Medical Center

    Dallas, Texasno site contact published

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, Franceno site contact published

  • Centre Hospitalier Regional Universitaire de Lille

    Lille, Franceno site contact published

  • Children's Hospital Los Angeles

    Los Angeles, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kite Study Director · STUDY_DIRECTOR · Kite, A Gilead Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

What this trial measures

  • Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)Up to 15 years

    Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and new malignancies.

  • Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)Up to 15 years

    Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and new malignancies.

  • Height of Pediatric and Adolescent ParticipantsUp to 15 years
  • Weight of Pediatric and Adolescent ParticipantsUp to 15 years
  • Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale ScoreUp to 15 years

    The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult.